Abstract
Neurodegenerative mechanisms due to mutations in spastin currently center on neuronal defects, primarily in microtubule and endomembrane regulation. Spastin loss in Drosophila larvae compromises neuronal microtubule distribution, alters synaptic bouton morphology, and weakens synaptic transmission at glutamatergic neuromuscular junction (NMJ) synapses. Pak3, a p21-activated kinase that promotes actin polymerization and filopodial projections, is required for these spastin mutant defects; animals lacking both genes have normal NMJs. Here we show that Pak3 is expressed in central and peripheral glial populations, and reduction of Pak3 specifically in subperineurial glial cells is sufficient to suppress the phenotypes associated with spastin loss. Subperineurial glia in the periphery ensheathe motor neuron axons and have been shown to extend actin-based projections that regulate synaptic terminals during normal NMJ development. We find that these subperineurial glial projections are Pak3-dependent and nearly twice as frequent in spastin mutants, while in Pak3, spastin double mutants, neither glial projections nor synaptic defects are observed. Spastin deficiency thus increases Pak3-dependent subperineurial glia activity, which is in turn required for neuronal defects. Our results demonstrate a central role for Pak3-mediated, altered glial behavior in the neuronal defects due to spastin loss, and suggest that a similar reactive glia-mediated mechanism may underlie human AD-HSP pathogenesis.
Introduction
The identification of human SPAST as the most common gene mutated in Autosomal-Dominant Hereditary Spastic Paraplegia two decades ago was a major advance, enabling multiple model systems to be leveraged toward understanding the requirement for Spastin in nervous system function (). Spastin likely serves to coordinately regulate the microtubule cytoskeleton and membrane components (reviewed in ), and although clear consensus is still in progress, several working hypotheses have emerged for its neuronal roles. Potential processes include neural stem cell proliferation (), remodeling the endoplasmic reticulum and other endomembrane components (e.g., ; ), lipid droplet function (; ), axon regeneration (), axon outgrowth (), axon transport (; ), and synaptic morphology and transmission (; ).
Drosophila spastin was identified in a forward screen for genes involved in nervous system development (). Just as SPAST mutations impair the longest axons of the central nervous system in humans, diminishing patient mobility, homozygous deletion of Drosophila spastin (the spastin5.75 allele) impairs mobility in adult flies, with the distal-most limbs also appearing the weakest. These adult flies are rarely viable, and although homozygous null larvae appear healthy, electrophysiological analysis of the larval neuromuscular junction (NMJ), a well-established model for vertebrate glutamatergic central synapses (), reveals reduced synaptic transmission due to defects at the presynaptic terminal (; ). This functional weakening is accompanied by distinctive changes in presynaptic arbor morphology. In contrast to wild type NMJs, spastin5.75 larvae have more highly branched axon terminal arbors, with smaller and more numerous synaptic boutons that often form bunched, rather than linear, arrays. Subcellularly, the normally continuous microtubule cytoskeleton appears sparse or undetectable in mutant terminal boutons, suggesting that Spastin’s microtubule severing activity is required for the generation and/or penetration of microtubules into distal sites. Consistent with this model, recent in vitro studies have shown that Spastin promotes stabilization and subsequent growth of severed microtubules, in addition to its well-established severing activity (; ). These subcellular, morphological, and functional phenotypes in spastin mutants are all significantly rescued by low-level, neuron-specific expression of fly – or human – wild type Spastin, demonstrating that Spastin function is well-conserved between flies and humans, and is required within neurons (; ).
To understand the molecular and cellular mechanisms underlying the consequences of spastin loss, we executed a forward genetic screen for modifiers of spastin mutant phenotypes and identified Pak3, a member of the p21-activated serine/threonine kinase family (). Pak proteins are conserved from amoebae to humans, and typically activated downstream of Rac and Cdc42 small GTPase signaling, leading to alterations in the actin cytoskeleton and phosphorylation of a wide range of other protein targets (reviewed in ; ). The Paks are particularly well-studied because of their demonstrated roles inducing cell motility, invasion, and metastasis in several cancers, as well as contributing to cardiac and neurological disorders. Humans have six PAK genes (PAK 1–6), segregated into two structurally distinct groups. The group I PAKs, characterized by highly conserved autoinhibitory (AID) and kinase domains, form inactive dimers that depend upon Rac or Cdc42 binding for relief of autoinhibition and subsequent kinase activity. The group II PAKs lack an AID and do not require RhoGTPase binding for kinase activity. Of the proteins encoded by the three Drosophila Pak genes, Pak, mushroom bodies tiny (mbt), and Pak3, Pak is orthologous to the group I vertebrate Paks, mbt falls clearly into the group II subfamily, and Pak3, while less similar than Pak, is also considered a group I Pak due to its clear AID and ∼60% amino acid identity in the kinase domain (). Both overexpression and knockdown of Drosophila Pak3 in various cell lines alters actin distribution and cell motility (; ; ). In vivo, Pak3 is important in dorsal closure (), epidermal wound healing (), podosome invasion during myoblast fusion (), and border cell migration during oogenesis (), all processes that require rearrangements of the actin cytoskeleton and changes in cell motility downstream of Rac signaling.
At the larval NMJ, ubiquitous, genetic loss of Pak3 does not significantly affect synapse form or function; however, Pak3 reduction in a spastin deficient background dramatically rescues the defects that characterize spastin mutants at this stage (). NMJ synapses in Pak3, spastin double mutants exhibit near-wild type morphology, with large and linearly-arrayed synaptic boutons. Subcellularly, continuity of the microtubule cytoskeleton within boutons is restored, and functionally, synaptic strength is indistinguishable from wild type levels. Absence of Pak3 thus renders these neurons resistant to spastin loss.
Given this striking rescue, we sought to understand how the presence of Pak3 confers spastin mutant phenotypes. We examined the Pak3 expression pattern and used tissue-specific knockdown to determine the cells in which it acts when spastin is lost. Surprisingly, Pak3 is not required in the motor neurons where Spastin functions, but rather, in the peripheral glia that ensheathe them. These glia provide essential support to the motor neurons, including extending filopodial projections that regulate the neuronal bouton arbor during development (; ). We find that Pak3 promotes glial projections at the NMJ. Furthermore, in spastin mutants these glial projections are more numerous, while reduction of glial Pak3 suppresses both the projections and spastin mutant bouton morphology. Together, these data support a model in which spastin loss leads to increased Pak3-mediated glial activity, changing glial behavior such that they become toxic, rather than supportive, to synaptic terminals. Increasing evidence of a central role for reactive glial behavior in the progression of several major neurodegenerative diseases () makes these results particularly intriguing, as it suggests that pathogenesis in AD-HSP may be similarly mediated by reactive, toxic changes in a normally supportive subpopulation of glia.
Materials and Methods
Drosophila Stocks and Sources
Stocks and crosses were maintained on standard molasses-based food (Archon Scientific), except for experiments using the flower (fwe) loss of function alleles, fweDB56 and fweDB25 (gift of H. Bellen), which were raised on yeasted grape juice plates to facilitate recovery of the desired genotypes. All larvae and adults assayed were from crosses kept at 25°C. Unless otherwise specified, controls were w1118 flies, the common genetic background for transgenic strains; their NMJs are indistinguishable from wild type flies so are also referred to here as “wild type.” Driver lines were repo-GAL4 (gift of M. Freeman), gliotactin (gli)-GAL4 (gift of V. Auld), e22c-Gal4 spaghetti-squash (sqh)-GAL4 (gift of D. Kiehart), breathless (btl)-GAL4 (gift of M. Metzstein), and elavC155-GAL4, Mef2-GAL4, Mhc-GAL4, and nSyb-GAL4 (all from the Bloomington Drosophila Stock Center, BDSC). Pak3 alleles were PBac{RB}Pak3e00329, P{XP}Pak3d02472 (abbreviated Pak3d in Figures 3, 4; BDSC), GAL4 insertion line P{GawB}Pak3NP4472 (Kyoto Drosophila Genomics and Genetic Resources Center), and RNAi lines Pak3NIG.14895R–2 (National Institute of Genetics, NIG-FLY), Pak3GL00287 (P{TRiP.GL00287}attB, BDSC), and Pak3v39844 (P{GD8481}v39844, Vienna Drosophila Resource Center). Generation of the deletion allele Df(3R)Pak3 (abbreviated Pak3Df in Figures 3, 4), was previously described (). UAS-Pak3::GFP constructs (gift of B. Baum) were injected into Drosophila embryos and two lines established: one insertion on chromosome II, UAS-Pak350::GFP, and one on chromosome III, UAS-Pak332::GFP. Tissue-specific expression of UAS-Pak350::GFP rescues Pak3 mutant adult lethality, consistent with the transgene producing functional Pak3 protein (E.F.O., unpublished results). UAS-Pak332::GFP was used for Pak3 overexpression in glia. Tissue-specific GFP was expressed using UAS-mCD8::GFP or UAS-nls::GFP flies (BDSC).
Immunofluorescence
Wandering third-instar larvae were dissected in room temperature Phosphate Buffered Saline (PBS, Invitrogen) or HL3 Ringer’s medium without Ca2+ for < 20 min., or when quantifying glial projections, in HL3 Ringer’s containing 1.5 mM Ca2+ for <10 min. prior to fixation. Filets were then fixed in 4% paraformaldehyde (Electron Microscopy Sciences) for 30 min., washed in PBS with 0.2% Triton X-100 (PBST), and blocked in PBST with 5% normal goat serum, 0.01% bovine serum albumin, and 0.01% sodium azide for up to 2 h at room temperature. Filets were incubated overnight at 4°C in primary antibody diluted in block. Primary antibodies used were mouse polyclonal αPak3 (gift of S. Bahri, 1:250), rabbit αHRP (Jackson, 1:100), mouse αDLG (4F3 supernatant, Developmental Studies Hybridoma Bank [DSHB], 1:100), rat αElav (7E8A10, DSHB, 1:100), mouse αSlit (C555.6D, DSHB, 1:50), and mouse (mAb 3E6) or rabbit αGFP (Invitrogen, 1:300). Filets were then washed in PBST and incubated with the species-appropriate Alexa Fluor 488 or 568 secondary antibodies (Invitrogen) diluted 1:300 in block, for 2 h at room temperature or overnight at 4°C. After further washing, filets were mounted in Vectashield (Vector Laboratories) or ProLong Antifade (ThermoFisher).
Synaptic Bouton and Glial Quantification and Imaging
Slide-mounted filets were scored with the experimenter blinded to larval genotypes, using an inverted fluorescence compound microscope (Zeiss Axiophot with a 63X, 1.2NA oil immersion objective or Zeiss Axio Imager with a 100X, 1.4NA oil immersion objective). Representative confocal images were obtained using a Zeiss 880 Airyscan confocal microscope and 63X, 1.2NA oil immersion or a 20X, 0.8NA dry objective. Images were false-colored magenta in Adobe Photoshop to aid visualization by color blind readers. Abdominal muscle 4 was identified for each hemisegment and type 1b synaptic bouton numbers were recorded. Type 1b bouton identity was confirmed by double staining with anti-DLG whenever possible (in all larvae for which anti-GFP immunostaining was not needed); otherwise, they were distinguished from type 1s boutons based on size and branch morphology. Terminal boutons, a measurement of synaptic arbor branching, were defined as any synaptic bouton with only one connection. This included all termini along the arbor and at the distal tips, regardless of size. Subperineurial glial projections were visualized using anti-GFP to visualize gliotactin-GAL4-driven expression of UAS-mCD8::GFP. Glial morphology at each main axon branch was characterized as (1) blunt, ending at synaptic boutons, (2) broad lamellipodia extending over synaptic boutons, (3) long, thin filopodia (gliopods) extending over synaptic boutons, away from the axon, or to neighboring axons, or (4) rounded structures (gliobulbs) that resemble boutons. Numbers of gliopods and gliobulbs were combined as a measure of glial projections. Glial and bouton counts from individual hemisegments were averaged for each larva and all values plotted as bee-swarm superplots using GraphPad Prism (). Statistical significance of larval means was determined by two-tailed Student’s t-test in Microsoft Excel (Figure 2 and Supplementary Figure S1) or one-way ANOVA with Sidak’s post hoc test for multiple comparisons in GraphPad Prism (Figures 3, 4). P-values are denoted as ns for p > 0.05, ∗ for 0.01 < p ≤ 0.05, ∗∗ for 0.001 < p ≤ 0.01, and ∗∗∗ for p ≤ 0.001.
Results
Pak3 Is Expressed in Larval Glia
To begin to identify the specific cells in which Pak3 loss prevents spastin mutant defects, we used a polyclonal antibody directed against the Drosophila Pak3 protein (kind gift of Sami Bahri; ) to determine its endogenous expression pattern in larvae. Anti-Pak3 staining in wild type controls was strongly detected in the ventral nerve cord (VNC, analogous to the spinal cord of vertebrates) in a dashed pattern characteristic of midline glial cells (Figure 1A, arrow). Immunofluorescence was also seen in a thin layer on the surface of the larval brain, and along axonal projections emanating from the brain and ventral nerve cord (Figure 1A, arrowheads). The strength of the antibody signal correlated with predicted protein expression levels consistent with RNA disruption in different Pak3 alleles, supporting the specificity of the antibody for Pak3 (compare Figures 1A–C).
FIGURE 1
Pak3 expression was also assessed using a Pak3 promoter and GFP reporter system. The Pak3 promoter-GAL4 transgenic line Pak3NP4472, in which the GAL4 gene is inserted 160 bp upstream of the Pak3 translational start site, was crossed to UAS-membrane GFP flies (UAS-mCD8::GFP;
Glial Knockdown of Pak3 Rescues the spastin Mutant Phenotype
Given that loss of Pak3 in the whole animal rescues the synaptic phenotype of spastin mutants, we next narrowed Pak3 knockdown to specific tissues and looked for the same rescuing effect. Using tissue-specific GAL4 expression to drive RNAi targeting Pak3 in a spastin null background (spastin5.75;
FIGURE 2

Glial, and specifically subperineurial glial, knockdown of Pak3 rescues spastin synaptic defects. (A–I) Anti-HRP staining shows neuronal morphology at the NMJ. The area within the box is magnified below. (A–C) are genetic background controls in which Pak3RNAi is not expressed via GAL4 activation (A wild type; B,C: spastin5.75 mutant); (D–I) are representative arbors from spastin5.75 mutants in which Pak3RNAi is expressed in the specified tissues. (A) Wild type synaptic boutons are arrayed linearly with few branches, while (B)spastin5.75 loss of function mutants have highly branched arbors with many small, bunched boutons. (C) In the absence of a GAL4 driver, the Pak3RNAi transgene has little effect on spastin5.75 morphology; terminal boutons remain significantly increased compared to wild type. (D) Ubiquitous expression of Pak3RNAi in the spastin5.75 background yields terminal boutons more similar in size, arrangement, and number to wild type. (E)Pak3RNAi expression in neurons does not rescue the spastin mutant phenotype, but (F,G)Pak3 knockdown in all except midline glia with repo-GAL4(F), or in subperineurial glia with gliotactin-GAL4(G), significantly rescues spastin5.75. (H,I) Knockdown of Pak3 in muscle (H) or trachea (I) show no difference in morphology from their spastin5.75 controls. (J) Synaptic morphologies are quantified by measuring the number of terminal boutons at each muscle 4 in a larva. In this and subsequent graphs, each open circle represents the quantity scored at an individual muscle; solid diamonds are the average of these counts for each larva, grouped by color; bars represent larval mean ± SEM; n(N) = number of larvae (number of muscles scored). “+” denotes two data points (y = 65 and 77) that fall outside of the y-axis range. The number of terminal boutons is statistically reduced compared to its driver-specific spastin5.75 control only when Pak3RNAi is expressed in glia or subperineurial glia. When compared to the spastin5.75 control, Pak3RNAi alleviates the spastin mutant phenotype if expressed ubiquitously, in all glia, or in subperineurial glia (p = 0.02). Statistical significance is calculated by Student’s t-test; asterisks signify p ≤ 0.001 (***), 0.001 < p ≤ 0.01 (**), or 0.01 < p ≤ 0.05 (*).
We then compared the consequence of Pak3 reduction using the pan-neuronal driver nSyb-GAL4 (
Pak3 Acts in the Subperineurial Glia
The Drosophila nervous system includes multiple glial cell types, each with distinct functions that bear striking molecular and behavioral parallels to vertebrate glial subtypes (reviewed in
SPG Projections Depend on Pak3 and Are Enhanced in spastin Mutants
How might Pak3 in subperineurial glia damage neuronal synapses? One possibility is that deleterious effects are mediated by the SPG projections that interact with the synaptic arbor. Given that Pak3 promotes actin polymerization and that these glial projections are actin-rich (
FIGURE 3

Subperineurial glia projections depend on Pak3 and are doubled in spastin mutants. (A–E) Anti-HRP shows neuronal morphology in magenta, anti-GFP shows glial morphology in green. (A)gli-GAL4, UAS-mCD8::GFP (gli > GFP) controls have linearly arrayed synaptic boutons and average one glial projection (arrowhead) per muscle 4. (B)Pak3 loss of function mutants, gli > GFP; Pak3Df/Pak3d02472 (abbreviated “Pak3Df/d”) have similarly arrayed bouton arbors but very few glial projections. (C)spastin5.75 loss of function, gli > GFP; spas, causes extra glial projections in addition to extra terminal boutons. These projections include thin glial filopodia (arrowheads) and round glial projections (arrows). (D) Consistent with these extra glial projections requiring Pak3 function, gli > GFP; Pak3Df, spas/Pak3d02472, spas double mutants display few glial projections, and have wild type bouton arbors. (E) Overexpression of Pak3 in subperineurial glia does not affect glial projections or terminal bouton numbers compared to controls, although small, clustered terminal boutons are observed. (F,G) Graphs of individual (open circles) and averaged (solid diamonds) values per larva for terminal boutons (F) and glial projections (G) are shown for each of the genotypes in (A–E). Significant differences relative to gli > GFP controls are calculated by one-way ANOVA followed by Sidak’s multiple comparisons test. P-values are denoted as * for 0.01 < p ≤ 0.05, and ** for 0.001 < p ≤ 0.01.
Given that Pak3 in SPG is necessary for spastin mutant synapses, we asked whether overexpression of Pak3 in wild type SPG is sufficient to elicit synaptic defects characteristic of spastin loss. Pak3 was overexpressed in GFP-labeled SPG using gli-GAL4 to drive expression of UAS-Pak3 and UAS-mCD8::GFP in an otherwise wild type background. UAS-Pak3 induces actin-rich projections in the synaptic bouton arbor when overexpressed in neurons (
Pak3-Mediated Toxicity Shows Specificity to spastin Loss
The striking efficacy of Pak3 removal in suppressing defects due to spastin loss suggested that Pak3-mediated changes in glial behavior might be a common mechanism underlying neuronal dysfunction. To test this possibility, we investigated genetic mutants in flower (fwe), which like spastin mutants, exhibit small, highly branched, supernumerary boutons (Figure 4;
FIGURE 4

Pak3 loss of function does not rescue all supernumerary bouton mutants. (A–D) Anti-HRP staining shows neuronal morphology at the NMJ. (A) Wild type synaptic boutons are arrayed linearly with only a few branches and (B)Pak3 loss of function mutants, Pak3Df/Pak3d02472, show no differences from wild type. (C) Loss of function mutations in flower (fweDB56/fweDB25) result in extreme branching of the neuronal arbor and small bouton size, similar to spastin mutant morphology. (D) Loss of Pak3 function does not rescue the supernumerary bouton phenotype in fwe mutants, indicating that Pak3 loss is not a generalized mechanism to reduce extra synaptic branching. (E) Individual terminal bouton numbers (open circles) and larval averages (solid diamonds) are shown for each of the genotypes in (A–D). Significant differences are calculated by one-way ANOVA and Sidak’s multiple comparisons test. * denotes 0.01 < p ≤ 0.05.
Discussion
Through an unbiased, forward genetic screen for modifiers of Spastin activity, we previously showed that the actin regulator Pak3 is required for the manifestation of morphological and functional synaptic defects due to spastin loss (
The ability of Pak3 loss to suppress spastin mutant defects suggests that Pak3-dependent glial projections are a critical aspect of SPG toxicity when spastin is lost. Excess glial projections could, for example, reflect phagocytic behavior gone awry, given that wild type projections positively regulate synaptic arbor morphology through this mechanism (
In addition to defining the contribution of these additional cell types, future experiments will be important to determine whether Pak3 is altered in response to spastin loss within the same SPG cells, or if changes in Pak3 are induced cell non-autonomously. Our earlier results used tissue-specific rescue to demonstrate that spastin is primarily required in neurons (
Although they remain the “support cells” of the nervous system, the idea that glia can also induce neuronal toxicity, particularly in the context of other defects, is increasingly evident. In flies, the requirement for Pak3 to elicit neuronal dysfunction during spastin loss bears striking parallels to the glial-derived, prodegenerative signaling molecule Eiger (the mammalian TNF-α ortholog;
Dramatic changes in glial morphology and behavior, from non-reactive to reactive states, are also observed in mammalian nervous systems in response to damage (reviewed in
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.
Author contributions
EO and NS contributed to the conception and experimental design. JW, SE, and HA generated and characterized genetic tools, including the efficacy of GAL4 drivers and RNAi lines, and obtained pilot data on bouton and glial phenotypes. EO performed dissections and immunofluorescence with anti-Pak3, -Slit, -Elav, and -GFP, and quantified adult eclosion rates, boutons for the fwe mutant experiment, and glial projections. EO, NS, and HA performed genetic crosses, larval dissections, immunofluorescence, acquired confocal images, and performed statistics on numeric data for the tissue-specific RNAi experiments. NS wrote the first draft of the manuscript. EO compiled the figures and figure legends and contributed to manuscript revision. All authors read and approved the written work.
Funding
This work was enabled by generous funding from the Shepard Broad Foundation, Raquelle de la Rocha, and the GT-Hele Fund. Publication costs were supported by the Duke University Libraries’ Compact for Open Access Publishing Equity (COPE) Fund to remove cost barriers in making Duke research open.
Acknowledgments
We are grateful to Buzz Baum, Sami Bahri, Marc Freeman, Vanessa Auld, Hugo Bellen, Mark Metzstein, and Donald Fox for generously sharing reagents and fly stocks, as well as to Nicole Fox, Jaeda Coutinho-Budd, and Eric Monson for helpful discussions. We thank former lab members, particularly Charlene Chen, Caitlin Cristante, and Daniel Ren for their assistance with the fwe mutant experiments. Additional stocks were obtained from the Bloomington Drosophila Stock Center (NIH P40OD018537), National Institute of Genetics (NIG-FLY, Japan), Kyoto Drosophila Genomics and Genetics Resources (DGGR, Kyoto Institute of Technology), and the Vienna Drosophila Resource Center (VDRC, www.vdrc.at). Monoclonal antibodies were obtained from the Developmental Studies Hybridoma Bank, created by the NICHD of the NIH and maintained at The University of Iowa, Department of Biology. Duke’s Light Microscopy Core Facility, the D. Sherwood lab, and E. Spana provided valuable microscopy support.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnins.2020.00912/full#supplementary-material
FIGURE S1Ubiquitous or glial-specific Pak3RNAi expression in wild type versus spastin mutant backgrounds suppresses the effects of spastin mutation. From left to right: Loss of spastin in Controls induces a nearly twofold increase in total bouton number (left two genotypes), and this effect is not altered by the presence of the Pak3RNAi transgene (next two genotypes). Ubiquitous Pak3RNAi expression makes larval synapses resistant to spastin removal, as bouton numbers in wild type (left; e,sqh > Pak3[RNAi]) and spastin mutant (right; e,sqh > Pak3[RNAi],spas) backgrounds are not significantly different. Neither neuron- nor muscle-specific Pak3RNAi expression suppress supernumerary boutons in spastin mutants. These results are consistent with those of Figure 2. The effects of tracheal Pak3RNAi expression are inconclusive, as the btl-GAL4 driver alone may suppress the spastin mutant phenotype independent of Pak3 (see Figure 2). Statistical significance is determined by Student’s t-test. P-values are denoted as ns for p > 0.05, * for 0.01 < p ≤ 0.05, ** for 0.001 < p ≤ 0.01, and *** for p ≤ 0.001.
FIGURE S2Expression of two different Pak3 RNAi transgenes, and use of a different pan-neuronal driver, independently support alleviation the spastin mutant phenotype by glial, and not neuronal, Pak3 knockdown. Simultaneous pan-neuronal expression of the Pak3GL0028 and Pak3v39844 RNAi transgenes (“Pak3[2xRNAi]”) does not alleviate supernumerary boutons of spastin mutants (p = 0.32 compared to paired control). The neuronal driver used in these experiments is elavC155-GAL4 rather than nsyb-GAL4; Dcr2 was also expressed to increase RNAi efficacy. In contrast, pan-glial expression of these Pak3 RNAi transgenes has the same effect as Pak3NIG.14895R–2 RNAi expression (from Figure 2 and Supplementary Figure S1), reducing terminal bouton number in spastin mutants to wild type levels (p = 1.3 × 10–3; Student’s t-test).
References
1
AllisonR.EdgarJ. R.ReidE. (2019). Spastin MIT domain disease-associated mutations disrupt lysosomal function.Front. Neurosci.13:1179. 10.3389/fnins.2019.01179
2
AsanoY.Jimenez-DalmaroniA.LiverpoolT. B.MarchettiM. C.GiomiL.KigerA.et al (2009). Pak3 inhibits local actin filament formation to regulate global cell polarity.HFSP J.3194–203. 10.2976/1.3100548
3
BaekS. H.ChoH. W.KwonY. C.LeeJ. H.KimM. J.LeeH.et al (2012). Requirement for Pak3 in Rac1-induced organization of actin and myosin during Drosophila larval wound healing.FEBS Lett.586772–777. 10.1016/j.febslet.2012.01.061
4
BahriS.WangS.ConderR.ChoyJ.VlachosS.DongK.et al (2010). The leading edge during dorsal closure as a model for epithelial plasticity: pak is required for recruitment of the Scribble complex and septate junction formation.Development1372023–2032. 10.1242/dev.045088
5
BrinkD. L.GilbertM.XieX.Petley-RaganL.AuldV. J. (2012). Glial processes at the Drosophila larval neuromuscular junction match synaptic growth.PLoS One7:e37876. 10.1371/journal.pone.0037876
6
ChangC. L.WeigelA. V.IoannouM. S.PasolliH. A.XuC. S.PealeD. R.et al (2019). Spastin tethers lipid droplets to peroxisomes and directs fatty acid trafficking through ESCRT-III.J. Cell. Biol.2182583–2599. 10.1083/jcb.201902061
7
ChenP. Y.TsaiY. W.ChengY. J.GiangrandeA.ChienC. T. (2019). Glial response to hypoxia in mutants of NPAS1/3 homolog Trachealess through Wg signaling to modulate synaptic bouton organization.PLoS Genet.15:e1007980. 10.1371/journal.pgen.1007980
8
CollinsC. A.DiAntonioA. (2007). Synaptic development: insights from Drosophila.Curr. Opin. Neurobiol.1735–42. 10.1016/j.conb.2007.01.001
9
DickmanD. K.LuZ.MeinertzhagenI. A.SchwarzT. L. (2006). Altered synaptic development and active zone spacing in endocytosis mutants.Curr. Biol.16591–598. 10.1016/j.cub.2006.02.058
10
DraberovaE.VinopalS.MorfiniG.LiuP. S.SladkovaV.SulimenkoT.et al (2011). Microtubule-severing ATPase spastin in glioblastoma: increased expression in human glioblastoma cell lines and inverse roles in cell motility and proliferation.J. Neuropathol. Exp. Neurol.70811–826. 10.1097/NEN.0b013e31822c256d
11
DuF.OzdowskiE. F.KotowskiI. K.MarchukD. A.SherwoodN. T. (2010). Functional conservation of human Spastin in a Drosophila model of autosomal dominant-hereditary spastic paraplegia.Hum. Mol. Genet.191883–1896. 10.1093/hmg/ddq064
12
DuanR.JinP.LuoF.ZhangG.AndersonN.ChenE. H. (2012). Group I PAKs function downstream of Rac to promote podosome invasion during myoblast fusion in vivo.J. Cell. Biol.199169–185. 10.1083/jcb.201204065
13
FelixM.ChayengiaM.GhoshR.SharmaA.PrasadM. (2015). Pak3 regulates apical-basal polarity in migrating border cells during Drosophila oogenesis.Development1423692–3703. 10.1242/dev.125682
14
FrankeJ. D.MontagueR. A.KiehartD. P. (2005). Nonmuscle myosin II generates forces that transmit tension and drive contraction in multiple tissues during dorsal closure.Curr. Biol.152208–2221. 10.1016/j.cub.2005.11.064
15
FreemanM. R. (2015). Drosophila central nervous system glia.Cold Spring Harb Perspect Biol7:a020552. 10.1101/cshperspect.a020552
16
Fuentes-MedelY.AshleyJ.BarriaR.MaloneyR.FreemanM.BudnikV. (2012). Integration of a retrograde signal during synapse formation by glia-secreted TGF-beta ligand.Curr. Biol.221831–1838. 10.1016/j.cub.2012.07.063
17
Fuentes-MedelY.LoganM. A.AshleyJ.AtamanB.BudnikV.FreemanM. R. (2009). Glia and muscle sculpt neuromuscular arbors by engulfing destabilized synaptic boutons and shed presynaptic debris.PLoS Biol.7:e1000184. 10.1371/journal.pbio.1000184
18
HavlicekS.KohlZ.MishraH. K.ProtsI.EberhardtE.DenguirN.et al (2014). Gene dosage-dependent rescue of HSP neurite defects in SPG4 patients’ neurons.Hum. Mol. Genet.232527–2541. 10.1093/hmg/ddt644
19
HazanJ.FonknechtenN.MavelD.PaternotteC.SamsonD.ArtiguenaveF.et al (1999). Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia.Nat. Genet.23296–303. 10.1038/15472
20
Hilu-DadiaR.KurantE. (2019). Glial phagocytosis in developing and mature Drosophila CNS: tight regulation for a healthy brain.Curr. Opin. Immunol.6262–68. 10.1016/j.coi.2019.11.010
21
JenettA.RubinG. M.NgoT. T.ShepherdD.MurphyC.DionneH.et al (2012). A GAL4-driver line resource for Drosophila neurobiology.Cell. Rep.2991–1001. 10.1016/j.celrep.2012.09.011
22
JeongB.KimT. H.KimD. S.ShinW. H.LeeJ. R.KimN. S.et al (2019). Spastin contributes to neural development through the regulation of microtubule dynamics in the primary cilia of neural stem cells.Neuroscience41176–85. 10.1016/j.neuroscience.2019.05.024
23
KasherP. R.De VosK. J.WhartonS. B.ManserC.BennettE. J.BingleyM.et al (2009). Direct evidence for axonal transport defects in a novel mouse model of mutant spastin-induced hereditary spastic paraplegia (HSP) and human HSP patients.J. Neurochem.11034–44. 10.1111/j.1471-4159.2009.06104.x
24
KellerL. C.ChengL.LockeC. J.MullerM.FetterR. D.DavisG. W. (2011). Glial-derived prodegenerative signaling in the Drosophila neuromuscular system.Neuron72760–775. 10.1016/j.neuron.2011.09.031
25
KumarR.SanawarR.LiX.LiF. (2017). Structure, biochemistry, and biology of PAK kinases.Gene60520–31. 10.1016/j.gene.2016.12.014
26
KuoY. W.TrottierO.MahamdehM.HowardJ. (2019). Spastin is a dual-function enzyme that severs microtubules and promotes their regrowth to increase the number and mass of microtubules.Proc. Natl. Acad. Sci. U.S.A.1165533–5541. 10.1073/pnas.1818824116
27
LeeT.LuoL. (1999). Mosaic analysis with a repressible cell marker for studies of gene function in neuronal morphogenesis.Neuron22451–461. 10.1016/s0896-6273(00)80701-1
28
LiddelowS. A.BarresB. A. (2017). Reactive astrocytes: production, function, and therapeutic potential.Immunity46957–967. 10.1016/j.immuni.2017.06.006
29
LoganM. A. (2017). Glial contributions to neuronal health and disease: new insights from Drosophila.Curr. Opin. Neurobiol.47162–167. 10.1016/j.conb.2017.10.008
30
LordS. J.VelleK. B.MullinsR. D.Fritz-LaylinL. K. (2020). SuperPlots: communicating reproducibility and variability in cell biology.J. Cell. Biol.219:e202001064. 10.1083/jcb.202001064
31
LumbJ. H.ConnellJ. W.AllisonR.ReidE. (2012). The AAA ATPase spastin links microtubule severing to membrane modelling.Biochim. Biophys. Acta1823192–197. 10.1016/j.bbamcr.2011.08.010
32
MaD. L.ChiaS. C.TangY. C.ChangM. L.ProbstA.BurgunderJ. M.et al (2006). Spastin in the human and mouse central nervous system with special reference to its expression in the hippocampus of mouse pilocarpine model of status epilepticus and temporal lobe epilepsy.Neurochem. Int.49651–664. 10.1016/j.neuint.2006.05.008
33
MentzelB.RaabeT. (2005). Phylogenetic and structural analysis of the Drosophila melanogaster p21-activated kinase DmPAK3.Gene34925–33. 10.1016/j.gene.2004.12.030
34
OlivaC.SoldanoA.MoraN.De GeestN.ClaeysA.ErfurthM. L.et al (2016). Regulation of Drosophila brain wiring by neuropil interactions via a slit-robo-RPTP signaling complex.Dev. Cell.39267–278. 10.1016/j.devcel.2016.09.028
35
OzdowskiE. F.GayleS.BaoH.ZhangB.SherwoodN. T. (2011). Loss of Drosophila melanogaster p21-activated kinase 3 suppresses defects in synapse structure and function caused by spastin mutations.Genetics189123–135. 10.1534/genetics.111.130831
36
PapadopoulosC.OrsoG.MancusoG.HerholzM.GumeniS.TadepalleN.et al (2015). Spastin binds to lipid droplets and affects lipid metabolism.PLoS Genet.11:e1005149. 10.1371/journal.pgen.1005149
37
ParkS. H.ZhuP. P.ParkerR. L.BlackstoneC. (2010). Hereditary spastic paraplegia proteins REEP1, spastin, and atlastin-1 coordinate microtubule interactions with the tubular ER network.J. Clin. Invest.1201097–1110. 10.1172/JCI40979
38
RaneC. K.MindenA. (2019). P21 activated kinase signaling in cancer.Semin. Cancer Biol.5440–49. 10.1016/j.semcancer.2018.01.006
39
RibeiroS. A.D’AmbrosioM. V.ValeR. D. (2014). Induction of focal adhesions and motility in Drosophila S2 cells.Mol. Biol. Cell.253861–3869. 10.1091/mbc.E14-04-0863
40
SemenovaG.ChernoffJ. (2017). Targeting PAK1.Biochem. Soc. Trans.4579–88. 10.1042/BST20160134
41
SeppK. J.SchulteJ.AuldV. J. (2000). Developmental dynamics of peripheral glia in Drosophila melanogaster.Glia30122–133. 10.1002/(sici)1098-1136(200004)30:2<122::aid-glia2>3.0.co;2-b
42
SeppK. J.SchulteJ.AuldV. J. (2001). Peripheral glia direct axon guidance across the CNS/PNS transition zone.Dev. Biol.23847–63. 10.1006/dbio.2001.0411
43
SherwoodN. T.SunQ.XueM.ZhangB.ZinnK. (2004). Drosophila spastin regulates synaptic microtubule networks and is required for normal motor function.PLoS Biol.2:e429. 10.1371/journal.pbio.0020429
44
ShigaY.Tanaka-MatakatsuM.HayashiS. (1996). A nuclear GFP / beta-galactosidase fusion protein as a marker for morphogenesis in living Drosophila.Dev. Growth Diff.3899–106. 10.1046/j.1440-169x.1996.00012.x
45
StoneM. C.RaoK.GheresK. W.KimS.TaoJ.La RochelleC.et al (2012). Normal spastin gene dosage is specifically required for axon regeneration.Cell. Rep.21340–1350. 10.1016/j.celrep.2012.09.032
46
TarradeA.FassierC.CourageotS.CharvinD.VitteJ.PerisL.et al (2006). A mutation of spastin is responsible for swellings and impairment of transport in a region of axon characterized by changes in microtubule composition.Hum. Mol. Genet.153544–3558. 10.1093/hmg/ddl431
47
TrottaN.OrsoG.RossettoM. G.DagaA.BroadieK. (2004). The hereditary spastic paraplegia gene, spastin, regulates microtubule stability to modulate synaptic structure and function.Curr. Biol.141135–1147. 10.1016/j.cub.2004.06.058
48
VemuA.SzczesnaE.ZehrE. A.SpectorJ. O.GrigorieffN.DeaconescuA. M.et al (2018). Severing enzymes amplify microtubule arrays through lattice GTP-tubulin incorporation.Science361:eaau1504. 10.1126/science.aau1504
49
WoodJ. D.LandersJ. A.BingleyM.McDermottC. J.Thomas-McArthurV.GleadallL. J.et al (2006). The microtubule-severing protein Spastin is essential for axon outgrowth in the zebrafish embryo.Hum. Mol. Genet.152763–2771. 10.1093/hmg/ddl212
50
YaoC. K.LinY. Q.LyC. V.OhyamaT.HaueterC. M.Moiseenkova-BellV. Y.et al (2009). A synaptic vesicle-associated Ca2+ channel promotes endocytosis and couples exocytosis to endocytosis.Cell138947–960. 10.1016/j.cell.2009.06.033
51
YaoC. K.LiuY. T.LeeI. C.WangY. T.WuP. Y. (2017). A Ca2+ channel differentially regulates Clathrin-mediated and activity-dependent bulk endocytosis.PLoS Biol.15:e2000931. 10.1371/journal.pbio.2000931
52
YildirimK.PetriJ.KottmeierR.KlambtC. (2019). Drosophila glia: few cell types and many conserved functions.Glia675–26. 10.1002/glia.23459
Summary
Keywords
Spastin, Pak3, Autosomal Dominant Hereditary Spastic Paraplegia, p21-activated kinase, subperineurial glia, microtubule severing proteins, reactive glia
Citation
Ozdowski EF, Wentzell JS, Engert SM, Abbott H and Sherwood NT (2020) Suppression of spastin Mutant Phenotypes by Pak3 Loss Implicates a Role for Reactive Glia in AD-HSP. Front. Neurosci. 14:912. doi: 10.3389/fnins.2020.00912
Received
31 March 2020
Accepted
06 August 2020
Published
04 September 2020
Volume
14 - 2020
Edited by
Cahir Joseph O’Kane, University of Cambridge, United Kingdom
Reviewed by
Yong Qing Zhang, Chinese Academy of Sciences (CAS), China; J. Troy Littleton, Massachusetts Institute of Technology, United States; Mihaela Serpe, National Institutes of Health (NIH), United States
Updates

Check for updates
Copyright
© 2020 Ozdowski, Wentzell, Engert, Abbott and Sherwood.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Nina T. Sherwood, nina.sherwood@duke.edu
This article was submitted to Neurodegeneration, a section of the journal Frontiers in Neuroscience
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.